Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 2:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 1,035 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Clotting Disorder Clear all
Terminated No phase listed Observational

A Chart Review of Rituximab Plus Repeated Cycles of Dexamethasone

NCT02050581
View directory record Official record
Conditions
Idiopathic Thrombocytopenia Purpura
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
3 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Oct 26, 2026, 2:19 PM EDT
Completed Phase 4 Interventional Results available

Dose-Response Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A

NCT00289536
View directory record Official record
Conditions
Hemophilia A
Interventions
Antihemophilic factor, recombinant, manufactured protein-free
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
12 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
8
States / cities
Little Rock, Arkansas • Los Angeles, California • Peoria, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Oct 26, 2026, 2:19 PM EDT
Completed Phase 3 Interventional Results available

A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A

NCT01731600
View directory record Official record
Conditions
Congenital Bleeding Disorder, Haemophilia A
Interventions
turoctocog alfa pegol
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
0 Years to 11 Years · Male only
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
24
States / cities
Phoenix, Arizona • Long Beach, California • Orange, California + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 26, 2026, 2:19 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection

NCT05517811
View directory record Official record
Conditions
Liver Cancer, Esophageal Cancer, Colorectal Cancer, Lung Adenocarcinoma, Control, Pancreas Cancer, Biliary Cancer
Interventions
TEG indices
Diagnostic Test
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 99 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
2
States / cities
Aurora, Colorado • Highlands Ranch, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 26, 2026, 2:19 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids

NCT05653219
View directory record Official record
Conditions
Primary Immune Thrombocytopenia
Interventions
Ianalumab, Eltrombopag, Placebo
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
9
States / cities
Yuma, Arizona • Aurora, Colorado • Evanston, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 26, 2026, 2:19 PM EDT
Completed No phase listed Observational

ATHN 2: Factor Switching Study

NCT02546622
View directory record Official record
Conditions
Hemophilia
Interventions
Factor VIII Replacement Products for Hemophilia which were FDA approved after January 1, 2013, Factor IX Replacement Products for Hemophilia which were FDA approved after January 1, 2013
Biological
Lead sponsor
American Thrombosis and Hemostasis Network
Network
Eligibility
Not listed
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
27
States / cities
San Diego, California • Aurora, Colorado • New Haven, Connecticut + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2021 · Synced Oct 26, 2026, 2:19 PM EDT
Terminated Phase 3 Interventional Results available

Initial Treatment of Patients With Immune Thrombocytopenic Purpura

NCT00991939
View directory record Official record
Conditions
Immune Thrombocytopenic Purpura
Interventions
Dexamethasone USP Micronized, Prednisone
Drug
Lead sponsor
Carelon Research
Other
Eligibility
15 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
18
States / cities
New Orleans, Louisiana • Baltimore, Maryland • Boston, Massachusetts + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2014 · Synced Oct 26, 2026, 2:19 PM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B

NCT02053792
View directory record Official record
Conditions
Hemophilia B
Interventions
rIX-FP
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
Up to 70 Years · Male only
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
4
States / cities
Aurora, Colorado • Indianapolis, Indiana • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2022 · Synced Oct 26, 2026, 2:19 PM EDT
Completed Phase 1 Interventional

Lipid Lowering Agents to Limit Lipid Oxidation and Activation of Clotting System in Nephrotic Syndrome

NCT01845428
View directory record Official record
Conditions
Nephrotic Syndrome, Hyperlipidemia
Interventions
Pravastatin
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 70 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Oct 26, 2026, 2:19 PM EDT
Completed No phase listed Observational Results available

Surveillance of Safety and Efficacy of Wilate in Patients With Von Willebrand Disease

NCT01602419
View directory record Official record
Conditions
Von Willebrand Disease
Interventions
Patients using Wilate as standard of care
Other
Lead sponsor
Octapharma
Industry
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
4
States / cities
Torrance, California • Miami, Florida • Salt Lake City, Utah + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Oct 26, 2026, 2:19 PM EDT
Withdrawn Not applicable Interventional

Single Incision Versus Standard Laparoscopic Splenectomy

NCT01276561
View directory record Official record
Conditions
Hereditary Spherocytosis, Idiopathic Thrombocytopenic Purpura
Interventions
Single Incision Splenectomy, Laparoscopic Splenectomy
Procedure
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
1 Year to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 3, 2017 · Synced Oct 26, 2026, 2:19 PM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy Study of Flebogamma 5% DIF IGIV in Pediatric Subjects

NCT00634569
View directory record Official record
Conditions
Primary Immune Deficiency Disease
Interventions
Flebogamma 5% DIF
Biological
Lead sponsor
Instituto Grifols, S.A.
Industry
Eligibility
2 Years to 16 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
7
States / cities
St. Petersburg, Florida • Atlanta, Georgia • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2017 · Synced Oct 26, 2026, 2:19 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Prophylaxis Treatment & Characterizing Efficacy, Safety, & PK Of B-Domain Deleted Recombinant FVIII

NCT00543439
View directory record Official record
Conditions
Hemophilia A
Interventions
Moroctocog alfa (AF-CC)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
6 Months to 15 Years · Male only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
7
States / cities
Cincinnati, Ohio • Portland, Oregon • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2019 · Synced Oct 26, 2026, 2:19 PM EDT
Completed Phase 3 Interventional Results available

Study of Cyclosporine or Corticosteroids as an Adjunct to Plasma Exchange in Thrombotic Thrombocytopenic Purpura (TTP)

NCT00713193
View directory record Official record
Conditions
Thrombotic Thrombocytopenic Purpura
Interventions
Cyclosporine, Prednisone
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 3, 2023 · Synced Oct 26, 2026, 2:19 PM EDT
Completed No phase listed Observational

The Use of rFVIIa in Trauma Patients: A Multi-Center Case Registry

NCT00328133
View directory record Official record
Conditions
Traumatic Hemorrhage, Hemorrhagic Shock
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 10, 2012 · Synced Oct 26, 2026, 2:19 PM EDT
Not listed No phase listed Observational

Molecular and Clinical Studies of Primary Immunodeficiency Diseases

NCT00006319
View directory record Official record
Conditions
Wiskott- Aldrich Syndrome, ADA Deficient SCID
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
3 Years and older
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 26, 2026, 2:19 PM EDT
Completed No phase listed Observational

Quality of Life in Patients With Congenital Afibrinogenemia

NCT03484065
View directory record Official record
Conditions
Afibrinogenemia, Congenital
Interventions
Questionnaire quality of life
Other
Lead sponsor
University Hospital, Geneva
Other
Eligibility
8 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Orange, California • New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Oct 26, 2026, 2:19 PM EDT
Terminated Phase 2 Interventional

Use of Activated Recombinant Human Factor VII in Cardiac Surgery

NCT00154427
View directory record Official record
Conditions
Acquired Bleeding Disorder, Cardiac Surgery Requiring Cardiopulmonary Bypass
Interventions
activated recombinant human factor VII
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
18
States / cities
Birmingham, Alabama • Tucson, Arizona • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 26, 2026, 2:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Identifying the Anti-Blood-Clotting Compounds in Garlic

NCT00200785
View directory record Official record
Conditions
Arteriosclerosis, Intracranial Arteriosclerosis
Interventions
garlic powder added to ambient water, garlic powder added to boiling water
Dietary Supplement
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Orem, Utah
Source: ClinicalTrials.gov public record
Updated Jan 11, 2010 · Synced Oct 26, 2026, 2:19 PM EDT
Completed Phase 2 Interventional Results available

Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim

NCT01143038
View directory record Official record
Conditions
Idiopathic Thrombocytopenic Purpura
Interventions
Romiplostim
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
8
States / cities
Anaheim, California • Orange, California • Boynton Beach, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Oct 26, 2026, 2:19 PM EDT
Completed Phase 3 Interventional

Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment

NCT00008359
View directory record Official record
Conditions
Cancer
Interventions
caspofungin acetate, liposomal amphotericin B
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 26, 2026, 2:19 PM EDT
Recruiting Phase 4 Interventional

Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery

NCT05936580
View directory record Official record
Conditions
Hemophilia A
Interventions
Nuwiq
Drug
Lead sponsor
Octapharma
Industry
Eligibility
12 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 26, 2026, 2:19 PM EDT
Completed Phase 2 Interventional

Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)

NCT01259817
View directory record Official record
Conditions
High Risk Polycythemia Vera, High Risk Essential Thrombocythemia
Interventions
PEGASYS, Aspirin
Drug
Lead sponsor
Ronald Hoffman
Other
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
16
States / cities
Scottsdale, Arizona • Palo Alto, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 26, 2026, 2:19 PM EDT
Terminated Phase 2 Interventional Results available

Tranexamic Acid and Thromboelastography During Cesarean Delivery

NCT02026297
View directory record Official record
Conditions
Postpartum Hemorrhage
Interventions
Tranexamic Acid, Placebo; Normal Saline
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 27, 2020 · Synced Oct 26, 2026, 2:19 PM EDT